Zydus Lifesciences Ltd. and Torrent Pharmaceuticals Ltd. on Wednesday announced a co-marketing partnership to bring semaglutide injection products to Indian markets. The firms have inked a licensing and supply agreement to co-market the key Ozempic ingredient.
Zydus will take care of manufaturing and supply of the product while Torrent has obtained a semi-exclusive license to co-market the product under brand name 'SEMBOLIC'. Torrent Pharmaceuticals will leverage its "strong presence" in chronic therapies and "extensive field force" to do so, a statement said.
Zydus will market the semaglutide injection under its brands SEMAGLYNTM, MASHEMATM and ALTERMETM, while Torrent Pharma will market the product under its brand SEMBOLICTM. Torrent Pharma will also pay an upfront licensing fee to Zydus as per the agreement.
Semaglutide is used for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an add-on to the treatment process that also utiilises diet and exercise.
It is used in two distinct cases. In the first case, the product is used as monotherapy, as a substitute for the drug metformin, in the cases where it is considered inappropriate due to intolerance or contraindications.In the second case is used alongside other medicinal products to treat diabetes.
ALSO READ: Ozempic Patent Ends On March 20 And A Generic Deluge Is Coming Forcing Prices To Fall
It can also play a part in treatment plans for chronic weight management in adults where it can be coupled with a reduced-calorie diet and increased physical activity. Semgalutide is recommended for treatment of adults whose Body Mass Index (BMI) is more than or equal to 30 kg/m² (obesity) or 7 kg/m² (overweight) in the presence of at least one weight-related comorbidity such as hypertension, type 2 diabetes mellitus, or dyslipidaemia.
Zydus has developed a formulation of Semaglutide Injection (15 mg/3 ml) in a prefilled cartridge administered via a reusable patient-friendly pen device. This is intended to facilitate the delivery of all strengths for both indications through a single device platform.
"The formulation combined with the reusable pen device is designed to enhance patient convenience, improve treatment adherence, and support better long-term compliance, addressing key challenges in chronic disease management," the release said.
ALSO READ: Semaglutide Generics: Dr Reddy's, Sun, Alkem Set To Be Early Winners In $500 Million Obesity Market
Essential Business Intelligence, Continuous LIVE TV, Sharp Market Insights, Practical Personal Finance Advice and Latest Stories — On NDTV Profit.